BioHarvest Sciences Secures Dual Listing on Tel Aviv Stock Exchange
I'm LongbridgeAI, I can summarize articles.BioHarvest Sciences has dual-listed its common shares on the Tel Aviv Stock Exchange (TASE) under symbol BHST, following its Nasdaq listing. The company registered existing shares and reserves for TASE trading, with concurrent filings to Israel’s MAGNA system. Analysts maintain a 'Buy' rating with a $14 price target, while TipRanks’ AI assigns a 'Neutral' score due to weak financial quality despite strong gross margins.
BioHarvest Sciences ( (BHST) ) just unveiled an update.
BioHarvest Sciences Inc., a Vancouver-based foreign private issuer listed on the Nasdaq Capital Market, reported details of its capital structure in connection with a new exchange listing. The company’s 22.7 million outstanding common shares, equity incentive plan pool and investor warrants are now structured to trade across more than one market, enhancing visibility among U.S. and Israeli investors.
On September 3, 2026, BioHarvest announced plans to dual-list its common shares on the Tel Aviv Stock Exchange, and the shares began trading there on September 8, 2026 under the symbol BHST. The company registered all existing common shares, option and RSU reserves, and warrant-related shares for trading on TASE, and said future U.S. EDGAR filings will be concurrently submitted to Israel’s MAGNA system, signaling a deeper integration into Israeli capital markets.
The most recent analyst rating on (BHST) stock is a Buy
with a $14.00 price target.
To see the full list of analyst forecasts on BioHarvest Sciences stock,
see the BHST Stock Forecast page.
Spark’s Take on BHST Stock
According to Spark, TipRanks’ AI Analyst, BHST is a Neutral.
The score is held down primarily by weak financial quality (ongoing losses and persistent cash burn) and a bearish technical setup (price below key moving averages and negative MACD). Offsetting factors include strong gross margins and revenue progress, plus earnings-call positives around improved cash and longer-term CDMO opportunity—though these are tempered by lowered 2026 guidance and continued EBITDA losses.
To see Spark’s full report on BHST stock,
click here.
More about BioHarvest Sciences
BioHarvest Sciences Inc., headquartered in Vancouver, is a foreign private issuer listed on the Nasdaq Capital Market. The company has 22.7 million outstanding common shares and also maintains an equity incentive plan and investor warrants, reflecting a focus on capital markets access and share-based compensation for officers, employees and consultants.
BioHarvest’s securities activities place it firmly within the cross-border public company universe, with regulatory reporting in both the United States and Canada. Its growing suite of listed and issuable securities underpins investor relations efforts and supports future financing and employee incentive flexibility in multiple jurisdictions.
Average Trading Volume: 52,131
Technical Sentiment Signal: Buy
Current Market Cap: $41.94M
For an in-depth examination of BHST stock, go to TipRanks’ Overview page.